Pfizer accused of suppressing Neurontin study
Pharma Compliance Alert, October 15, 2008
Pfizer marketing executives allegedly knew Neurontin, an epilepsy drug, did not effectively treat other conditions and delayed the publication or altered the conclusions of studies to boost off-label sales through at least 2003, according to a Boston Globe article.
The information surfaced as part of documents and e-mails turned over for a potential class action lawsuit. Patients and insurers are suing Pfizer for consumer fraud and unjust enrichment, claiming the company marketed the drug for off-label uses.
According to the Globe, the documents show Pfizer kept a European study from being published in its entirety. Instead, Pfizer published the findings with data from other studies in a minor medical journal. At the same time, Pfizer allegedly aggressively promoted a smaller study with positive results.
Pfizer paid $430 million in 2004 for the alleged off-label promotion of Neurontin by Warner Lambert’s Parke-Davis division, which Pfizer later acquired.
Comments
0 comments on “Pfizer accused of suppressing Neurontin study ”
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Healthcare Marketing Advisor
Healthcare Marketing Advisor provides concise, time-saving strategies for branding, promoting, and advertising your...
-
Marketing Oncology: Strategies for Service Line Campaigns
During this 90-minute Webcast, expert healthcare marketers discuss the research and strategic planning that should be the...
-
The Complete Guide to Hospital Marketing, Second Edition
The Complete Guide to Hospital Marketing, Second Edition looks at the complex field of healthcare marketing in a...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- Q/A: Coding for telescopic intraocular lens
- New FAQ posted on storing laryngoscope blades
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- What does case-mix index mean to you?
- HHS task force: Consider privacy, security with text messages
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- COT basics to best
- Searched